A detailed history of Aspire Private Capital, LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Aspire Private Capital, LLC holds 700 shares of PBYI stock, worth $2,114. This represents 0.0% of its overall portfolio holdings.

Number of Shares
700
Previous 700 -0.0%
Holding current value
$2,114
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

BUY
$2.85 - $6.58 $570 - $1,316
200 Added 40.0%
700 $2,000
Q3 2021

Nov 15, 2021

BUY
$6.63 - $9.39 $3,315 - $4,695
500 New
500 $4,000
Q1 2021

May 26, 2021

SELL
$9.38 - $13.63 $4,690 - $6,815
-500 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$9.5 - $11.14 $4,750 - $5,570
500 New
500 $5,000
Q1 2020

May 14, 2020

SELL
$6.28 - $14.57 $3,140 - $7,285
-500 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$6.5 - $10.73 $1,950 - $3,219
300 Added 150.0%
500 $4,000
Q3 2019

Nov 12, 2019

BUY
$8.75 - $12.85 $1,750 - $2,570
200 New
200 $2,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $138M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Aspire Private Capital, LLC Portfolio

Follow Aspire Private Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aspire Private Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aspire Private Capital, LLC with notifications on news.